PF-Atlas › Clinical Trials › NCT00573326

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Imatinib · Phase 2

Registry ID

NCT00573326

Phase

Phase 2

Status

Unknown

Drug / intervention

Imatinib

Sponsor

Azienda Ospedaliera Universitaria Policlinico

Start

2009-02

About this trial

Imatinib is evaluated in NCT00573326, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Azienda Ospedaliera Universitaria Policlinico. Current status: Unknown.

View NCT00573326 on ClinicalTrials.gov →

Explore related

All Imatinib trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT00573326 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.